JP2019512495A - 急性骨髄性白血病の治療のための併用療法 - Google Patents

急性骨髄性白血病の治療のための併用療法 Download PDF

Info

Publication number
JP2019512495A
JP2019512495A JP2018548236A JP2018548236A JP2019512495A JP 2019512495 A JP2019512495 A JP 2019512495A JP 2018548236 A JP2018548236 A JP 2018548236A JP 2018548236 A JP2018548236 A JP 2018548236A JP 2019512495 A JP2019512495 A JP 2019512495A
Authority
JP
Japan
Prior art keywords
salt
amino
acute myeloid
myeloid leukemia
methylpiperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018548236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512495A5 (cg-RX-API-DMAC7.html
Inventor
エルクット バーチェジ
エルクット バーチェジ
陽子 山木
陽子 山木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JP2019512495A publication Critical patent/JP2019512495A/ja
Publication of JP2019512495A5 publication Critical patent/JP2019512495A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018548236A 2016-03-29 2017-03-27 急性骨髄性白血病の治療のための併用療法 Pending JP2019512495A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662314700P 2016-03-29 2016-03-29
US62/314700 2016-03-29
US201662368343P 2016-07-29 2016-07-29
US62/368343 2016-07-29
PCT/JP2017/012293 WO2017170348A1 (en) 2016-03-29 2017-03-27 Combination therapy for the treatment of acute myeloid leukemia

Publications (2)

Publication Number Publication Date
JP2019512495A true JP2019512495A (ja) 2019-05-16
JP2019512495A5 JP2019512495A5 (cg-RX-API-DMAC7.html) 2020-04-09

Family

ID=59965623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548236A Pending JP2019512495A (ja) 2016-03-29 2017-03-27 急性骨髄性白血病の治療のための併用療法

Country Status (10)

Country Link
US (2) US20190117649A1 (cg-RX-API-DMAC7.html)
EP (1) EP3436014A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019512495A (cg-RX-API-DMAC7.html)
KR (1) KR20180124055A (cg-RX-API-DMAC7.html)
CN (1) CN108883109A (cg-RX-API-DMAC7.html)
BR (1) BR112018069111A2 (cg-RX-API-DMAC7.html)
CA (1) CA3018155A1 (cg-RX-API-DMAC7.html)
MX (1) MX2018011975A (cg-RX-API-DMAC7.html)
RU (1) RU2018134167A (cg-RX-API-DMAC7.html)
WO (1) WO2017170348A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN113490497B (zh) * 2019-02-22 2025-04-04 韩美药品株式会社 包括flt3抑制剂和低甲基化剂的用于治疗急性髓系白血病的药物组合物
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
JP7577672B2 (ja) * 2019-02-22 2024-11-05 ハンミ ファーマシューティカルズ カンパニー リミテッド Ｆｌｔ３阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
MY204603A (en) 2019-04-03 2024-09-05 Astellas Pharma Inc Pharmaceutical composition
AU2020308814A1 (en) 2019-06-27 2022-02-03 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
US20230029336A1 (en) * 2019-10-14 2023-01-26 Astrazeneca Ab Combination Therapy for Treating a Hematological Malignancy
US20220387362A1 (en) * 2019-10-21 2022-12-08 Rhizen Pharmaceuticals Ag Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
KR102559124B1 (ko) 2022-08-25 2023-07-26 주식회사 엔젠바이오 Flt3 유전자 증폭용 조성물 및 이의 용도

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 128, no. 22, JPN6020049994, 2 December 2016 (2016-12-02), pages 2830, ISSN: 0004417084 *
EXPERT REVIEW OF HEMATOLOGY, vol. 9, no. 5, JPN6020049991, 17 March 2016 (2016-03-17), pages 433 - 445, ISSN: 0004563950 *
LEUKEMIA, vol. 30, JPN6020049993, 15 January 2016 (2016-01-15), pages 1025 - 1032, ISSN: 0004563951 *

Also Published As

Publication number Publication date
EP3436014A1 (en) 2019-02-06
WO2017170348A1 (en) 2017-10-05
EP3436014A4 (en) 2019-11-27
BR112018069111A2 (pt) 2019-03-19
US20190117649A1 (en) 2019-04-25
RU2018134167A3 (cg-RX-API-DMAC7.html) 2020-06-30
US20200360372A1 (en) 2020-11-19
CA3018155A1 (en) 2017-10-05
CN108883109A (zh) 2018-11-23
KR20180124055A (ko) 2018-11-20
RU2018134167A (ru) 2020-04-29
MX2018011975A (es) 2019-01-15

Similar Documents

Publication Publication Date Title
JP2019512495A (ja) 急性骨髄性白血病の治療のための併用療法
Khandelwal et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients
Welschinger et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice
US8003105B2 (en) Method of treating cancer by co-administration of anticancer agents
Humme et al. Systematic review of combination therapies for mycosis fungoides
JP2020203919A (ja) Ｆｌｔ３変異を有する急性骨髄性白血病の治療用の医薬組成物
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
JP2009102408A (ja) ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療
KR20200083532A (ko) 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
Davids et al. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Hughes et al. Treatment of patients with relapsed/refractory non-hodgkin lymphoma with venetoclax: a single-center evaluation of off-label use
AU2015219038B2 (en) Compositions and methods for treating neutropenia
WO2022090443A1 (en) Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
JP2021517144A (ja) Ｃｄ４７遮断療法およびｃｄ３８抗体の組み合わせ
JPWO2019016928A1 (ja) がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤
RU2746705C2 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
JP2021063014A (ja) 白血病治療薬
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
JP7186731B2 (ja) 血液ガンのためのｍｃｌ－１阻害剤と標準治療処置との組み合わせ、その使用及び医薬組成物
Smith et al. Differentiation therapy in poor risk myeloid malignancies: results of a dose finding study of the combination bryostatin-1 and GM-CSF
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia
WO2021079129A1 (en) Dosing regimen
CN111228264A (zh) 西达本胺联合cgb以及自体造血干细胞的应用及联合药物
CN116390735A (zh) 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210803